Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Govt eases visa, travel rules 8 months after Covid curbs

The government on Thursday decided to restore with immediate effect all existing visas, except electronic, tourist and medical categories

The government on Thursday decided to restore with immediate effect all existing visas, except electronic, tourist and medical categories. The visas were suspended almost eight months ago following the coronavirus outbreak and subsequent imposition of a nationwide lockdown.&nbsp;The Ministry of Home Affairs also announced giving permission to all Overseas Citizen of India and Person of Indian Origin card holders and all other foreign nationals to visit India for any purpose, except on a tourist visa.

New Delhi, PTI: The government on Thursday decided to restore with immediate effect all existing visas, except electronic, tourist and medical categories. The visas were suspended almost eight months ago following the coronavirus outbreak and subsequent imposition of a nationwide lockdown.
The Ministry of Home Affairs also announced giving permission to all Overseas Citizen of India (OCI) and Person of Indian Origin (PIO) card holders and all other foreign nationals to visit India for any purpose, except on a tourist visa.
The ministry said in a statement that in view of the situation arising out of the Covid-19 pandemic, the government had taken a series of steps to curtail the inward and outward movement of international passengers since February, 2020.
The government has now decided to make a graded relaxation in visa and travel restrictions for more categories of foreign nationals and Indian nationals who wish to enter or leave India.
Under this graded relaxation, the government has decided to restore with immediate effect all existing visas, except electronic visa, tourist visa and medical visa, the statement said.
If the validity of such visas has expired, fresh visas of appropriate categories can be obtained from Indian mission or post concerned.
Foreign nationals intending to visit India for medical treatment can apply afresh for a medical visa, including for their medical attendants.
Therefore, this decision will enable foreign nationals to come to India for various purposes such as business, conferences, employment, studies, research, medical purposes etc.
The government has also decided to permit all OCI and PIO card holders and all other foreign nationals intending to visit India for any purpose, except on a tourist visa, to enter by air or water routes through authorised airports and seaport immigration check posts.

Serum Institute gets nod to resume Covid vaccine trials

Drugs Controller General of India on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate

Drugs Controller General of India on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate. The DCGI, Dr V G Somani, has however, put certain conditions like taking extra care during screening, providing additional information in informed consent to be followed during the trials. The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of "an unexplained illness" in a volunteer.

New Delhi, PTI: Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.
The DCGI, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be "scrupulously" followed by Serum Institute of India (SII).
SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.
The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of ''an unexplained illness'' in a participant in the study.
On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said clinical trials for their coronavirus vaccine have resumed in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.
SII, which has partnered with AstraZeneca for manufacturing the vaccine candidate for Covid-19, on Tuesday submitted the recommendations of the Data and Safety Monitoring Board (DSMB), UK and DSMB, India, and requested for permission to restart enrolment in the clinical trial.
According to Tuesday's order issued by DCGI, the DSMB, UK, recommended that the investigators recommence all immunization in their clinical trials subject to certain conditions.
DSMB, India, also has recommended to continue the study and enroll the remaining participants in the clinical trial as per protocol subject to certain conditions.
According to the order, SII has submitted revised participant information sheet, revised informed consent form and additional safety monitoring plan for the evolved participants.

Russian vaccine: India ready for human trials & production

Russia has approached India for conducting phase-3 clinical trial and manufacturing of its Covid-19 vaccine Sputnik V by Indian firms

Russia has approached India for conducting phase-3 clinical trial and manufacturing of its Covid-19 vaccine Sputnik V by Indian firms. The Indian govt has said that it is working to facilitate Moscow's request. Niti Aayog member Dr V K Paul, who also chairs the national expert group on Covid-19 vaccine administration, has said that Indian scientists have looked at the data on Sputnik V, which is in the public domain now, and there would be a need for the phase-3 trial. Dr Kaul said that that there has been considerable movement on Russia's request and several Indian companies are currently studying the proposal.

New Delhi, PTI: India is considering Russia's request for conducting phase-3 clinical trial and manufacturing of its Covid-19 vaccine Sputnik V by Indian firms, officials said Tuesday. There has been "significant movement" on both these fronts and specific outcomes are expected soon.
Dr V K Paul, Member (Health) Niti Aayog, who also chairs the national expert group on Covid-19 vaccine administration, said the government attaches "great importance to this offer of partnership from a very special friend to this nation".
He said that Indian scientists have looked at the data on Sputnik V, which is in the public domain now, and there would be a need for the phase -3 trial.
&ldquo;We are paving way for such a phase-3 trial or bridging studies, as per requirements of the regulatory system, to be facilitated by the government of India," he told a press conference here.
The Russian government has approached the government of India through appropriate channels to consider the manufacturing of Sputnik V through Indian companies and also conducting its phase-3 clinical trials here, Paul said.
"On both the tracks there has been significant movement,&rdquo; he said.
Several Indian companies are currently studying the proposal, he said.
"The outreach has been extended to several companies in India and a few of them have come forward while others are in discussions with the Russian counterparts and the government is facilitating that process of how that connect can be made. And there may be specific outcomes very soon in that regard," Paul said.
It is a "win-win situation" for India and the world, he said, underlining the county's ability to manufacture high quality vaccine in large and significant quantities.
It is good for Russia, good for India, and also excess capacities or specific part of the capacities can be offered to the rest of the world, he said.
Sputnik V has been developed by Russia's Gamaleya Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund (RDIF). The vaccine has not been tested in phase-3 or larger clinical trials.

of india

Categories